Suicide Risk and Symptom Reduction in Patients Assigned to Placebo in Duloxetine and Escitalopram Clinical Trials: Analysis of the FDA Summary Basis of Approval Reports

Author： Khan Arif   Schwartz Kelly  

Publisher： Informa Healthcare

ISSN： 1040-1237

Source： Annals of Clinical Psychiatry (after Jan 1, 2004), Vol.19, Iss.1, 2007-01, pp. : 31-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective

By Laughren T.P.  

European Psychiatry, Vol. 16, Iss. 7, 2001-11 ,pp. : 418-423

Elsevier

Access to resources Recommend Favorite

Use of a placebo in clinical trials

By Emilien G.   Maloteaux J.   Seghers A.   Charles G.  

European Psychiatry, Vol. 13, Iss. 5, 1998-08 ,pp. : 254-263

Elsevier

Access to resources Recommend Favorite

Managing the risk of suicide in acute psychiatric inpatients: A clinical judgement analysis of staff predictions of imminent suicide risk

By Paterson Brodie   Dowding Dawn   Harries Clare   Cassells Clare   Morrison Rhona   Niven Catherine  

Journal of Mental Health, Vol. 17, Iss. 4, 2008-08 ,pp. : 410-423

Informa Healthcare

Access to resources Recommend Favorite

Clinical rating scales in suicide risk assessment 1

By Cochrane-Brink K.A.   Lofchy J.S.   Sakinofsky I.  

General Hospital Psychiatry, Vol. 22, Iss. 6, 2000-11 ,pp. : 445-451

Elsevier

Access to resources Recommend Favorite

Long-Term Suicide Risk in Forensic Psychiatric Patients

By Clarke Martin   Davies Steffan   Hollin Clive   Duggan Conor  

Archives of Suicide Research, Vol. 15, Iss. 1, 2011-01 ,pp. : 16-28

Routledge Ltd

Access to resources Recommend Favorite